Annual Revenue
$46.02 M
+$4.61 M+11.14%
31 December 2023
Summary:
EyePoint Pharmaceuticals annual revenue is currently $46.02 million, with the most recent change of +$4.61 million (+11.14%) on 31 December 2023. During the last 3 years, it has risen by +$11.58 million (+33.63%). EYPT annual revenue is now at all-time high.EYPT Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Revenue
$10.52 M
+$1.05 M+11.05%
30 September 2024
Summary:
EyePoint Pharmaceuticals quarterly revenue is currently $10.52 million, with the most recent change of +$1.05 million (+11.05%) on 30 September 2024. Over the past year, it has dropped by -$4.68 million (-30.77%). EYPT quarterly revenue is now -58.41% below its all-time high of $25.31 million, reached on 30 September 2014.EYPT Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Revenue
$45.71 M
-$4.68 M-9.28%
30 September 2024
Summary:
EyePoint Pharmaceuticals TTM revenue is currently $45.71 million, with the most recent change of -$4.68 million (-9.28%) on 30 September 2024. Over the past year, it has increased by +$3.19 million (+7.50%). EYPT TTM revenue is now -9.28% below its all-time high of $50.39 million, reached on 30 June 2024.EYPT TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EYPT Revenue Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +11.1% | -30.8% | +7.5% |
| 3 y3 years | +33.6% | +16.2% | +40.5% |
| 5 y5 years | +1471.7% | +319.4% | +289.7% |
EYPT Revenue High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +33.6% | -30.8% | +37.0% | -9.3% | +40.5% |
| 5 y | 5 years | at high | +1471.7% | -33.0% | +319.4% | -9.3% | +289.7% |
| alltime | all time | at high | >+9999.0% | -58.4% | >+9999.0% | -9.3% | >+9999.0% |
EyePoint Pharmaceuticals Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $10.52 M(+11.0%) | $45.71 M(-9.3%) |
| June 2024 | - | $9.48 M(-18.9%) | $50.39 M(+0.7%) |
| Mar 2024 | - | $11.68 M(-16.7%) | $50.02 M(+8.7%) |
| Dec 2023 | $46.02 M(+11.1%) | $14.03 M(-7.7%) | $46.02 M(+8.2%) |
| Sept 2023 | - | $15.20 M(+67.0%) | $42.52 M(+13.9%) |
| June 2023 | - | $9.11 M(+18.5%) | $37.33 M(-6.2%) |
| Mar 2023 | - | $7.68 M(-27.1%) | $39.79 M(-3.9%) |
| Dec 2022 | $41.40 M(+12.1%) | $10.53 M(+5.2%) | $41.40 M(-2.4%) |
| Sept 2022 | - | $10.01 M(-13.4%) | $42.41 M(+2.3%) |
| June 2022 | - | $11.56 M(+24.4%) | $41.46 M(+6.6%) |
| Mar 2022 | - | $9.29 M(-19.5%) | $38.91 M(+5.3%) |
| Dec 2021 | $36.94 M(+7.3%) | $11.54 M(+27.4%) | $36.94 M(+13.6%) |
| Sept 2021 | - | $9.06 M(+0.5%) | $32.53 M(-16.9%) |
| June 2021 | - | $9.01 M(+23.1%) | $39.16 M(+14.3%) |
| Mar 2021 | - | $7.32 M(+2.7%) | $34.27 M(-0.5%) |
| Dec 2020 | $34.44 M(+69.1%) | $7.13 M(-54.6%) | $34.44 M(-4.2%) |
| Sept 2020 | - | $15.70 M(+280.8%) | $35.94 M(+58.0%) |
| June 2020 | - | $4.12 M(-45.0%) | $22.75 M(-12.0%) |
| Mar 2020 | - | $7.49 M(-13.3%) | $25.84 M(+26.9%) |
| Dec 2019 | $20.36 M(+595.5%) | $8.63 M(+244.1%) | $20.36 M(+73.6%) |
| Sept 2019 | - | $2.51 M(-65.2%) | $11.73 M(+20.8%) |
| June 2019 | - | $7.21 M(+258.3%) | $9.71 M(+202.1%) |
| Mar 2019 | - | $2.01 M(+314.0%) | $3.21 M(+4.9%) |
| Dec 2018 | $2.93 M(-1.1%) | - | - |
| Sept 2018 | - | $486.00 K(-32.0%) | $3.06 M(+3.4%) |
| June 2018 | $2.96 M(-60.7%) | $715.00 K(-23.0%) | $2.96 M(+0.5%) |
| Mar 2018 | - | $928.00 K(-0.5%) | $2.95 M(+13.0%) |
| Dec 2017 | - | $933.00 K(+142.3%) | $2.61 M(-65.9%) |
| Sept 2017 | - | $385.00 K(-45.1%) | $7.65 M(+1.4%) |
| June 2017 | $7.54 M(+365.4%) | $701.00 K(+18.8%) | $7.54 M(+5.6%) |
| Mar 2017 | - | $590.00 K(-90.1%) | $7.14 M(+3.9%) |
| Dec 2016 | - | $5.97 M(+2055.6%) | $6.88 M(+380.5%) |
| Sept 2016 | - | $277.00 K(-8.9%) | $1.43 M(-11.7%) |
| June 2016 | $1.62 M(-93.9%) | $304.00 K(-6.2%) | $1.62 M(-6.1%) |
| Mar 2016 | - | $324.00 K(-38.4%) | $1.73 M(-0.2%) |
| Dec 2015 | - | $526.00 K(+12.9%) | $1.73 M(+0.3%) |
| Sept 2015 | - | $466.00 K(+13.9%) | $1.72 M(-93.5%) |
| June 2015 | $26.57 M(+664.9%) | $409.00 K(+24.7%) | $26.57 M(+0.4%) |
| Mar 2015 | - | $328.00 K(-37.0%) | $26.45 M(-5.9%) |
| Dec 2014 | - | $521.00 K(-97.9%) | $28.11 M(-0.3%) |
| Sept 2014 | - | $25.31 M(+8566.8%) | $28.18 M(+711.5%) |
| June 2014 | $3.47 M(+62.1%) | $292.00 K(-85.3%) | $3.47 M(-5.4%) |
| Mar 2014 | - | $1.99 M(+236.5%) | $3.67 M(+67.4%) |
| Dec 2013 | - | $592.00 K(-0.8%) | $2.19 M(+0.3%) |
| Sept 2013 | - | $597.00 K(+21.3%) | $2.19 M(+2.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2013 | $2.14 M(-39.2%) | $492.00 K(-4.1%) | $2.14 M(-8.8%) |
| Mar 2013 | - | $513.00 K(-12.3%) | $2.35 M(-1.1%) |
| Dec 2012 | - | $585.00 K(+5.8%) | $2.38 M(-1.9%) |
| Sept 2012 | - | $553.00 K(-20.9%) | $2.42 M(-31.4%) |
| June 2012 | $3.53 M(-29.0%) | $699.00 K(+29.9%) | $3.53 M(-46.1%) |
| Mar 2012 | - | $538.00 K(-14.6%) | $6.54 M(+2.8%) |
| Dec 2011 | - | $630.00 K(-62.0%) | $6.36 M(+3.5%) |
| Sept 2011 | - | $1.66 M(-55.3%) | $6.15 M(+23.8%) |
| June 2011 | $4.96 M(-78.5%) | $3.71 M(+931.9%) | $4.96 M(-70.7%) |
| Mar 2011 | - | $360.00 K(-13.0%) | $16.97 M(-0.9%) |
| Dec 2010 | - | $414.00 K(-13.0%) | $17.13 M(-15.0%) |
| Sept 2010 | - | $476.00 K(-97.0%) | $20.15 M(-12.6%) |
| June 2010 | $23.05 M(+89.5%) | $15.72 M(+2952.8%) | $23.05 M(+118.4%) |
| Mar 2010 | - | $515.00 K(-85.0%) | $10.55 M(-20.1%) |
| Dec 2009 | - | $3.43 M(+1.5%) | $13.20 M(+3.6%) |
| Sept 2009 | - | $3.38 M(+5.0%) | $12.74 M(+4.7%) |
| June 2009 | $12.16 M(+249.9%) | $3.22 M(+1.9%) | $12.16 M(+4.5%) |
| Mar 2009 | - | $3.16 M(+6.5%) | $11.64 M(+29.1%) |
| Dec 2008 | - | $2.97 M(+5.8%) | $9.02 M(+46.0%) |
| Sept 2008 | - | $2.81 M(+3.8%) | $6.18 M(+77.8%) |
| June 2008 | $3.48 M(+55.5%) | $2.70 M(+398.7%) | $3.48 M(+183.1%) |
| Mar 2008 | - | $542.00 K(+323.4%) | $1.23 M(+63.5%) |
| Dec 2007 | - | $128.00 K(+24.3%) | $751.00 K(-33.6%) |
| Sept 2007 | - | $103.00 K(-77.4%) | $1.13 M(-37.8%) |
| June 2007 | $2.23 M(+52.6%) | $455.00 K(+600.0%) | $1.82 M(+2.6%) |
| Mar 2007 | - | $65.00 K(-87.2%) | $1.77 M(-13.9%) |
| Dec 2006 | - | $508.00 K(-35.7%) | $2.06 M(-7.3%) |
| Sept 2006 | - | $790.40 K(+93.1%) | $2.22 M(+23.0%) |
| June 2006 | $1.47 M(+134.7%) | $409.30 K(+16.3%) | $1.81 M(+17.3%) |
| Mar 2006 | - | $351.90 K(-47.5%) | $1.54 M(+14.2%) |
| Dec 2005 | - | $670.70 K(+78.8%) | $1.35 M(+60.5%) |
| Sept 2005 | - | $375.10 K(+161.9%) | $840.50 K(+36.4%) |
| June 2005 | $624.30 K(+135.4%) | $143.20 K(-10.7%) | $616.10 K(+18.6%) |
| Mar 2005 | - | $160.40 K(-0.9%) | $519.50 K(+20.3%) |
| Dec 2004 | - | $161.80 K(+7.4%) | $432.00 K(+26.3%) |
| Sept 2004 | - | $150.70 K(+223.4%) | $342.00 K(+33.5%) |
| June 2004 | $265.20 K(+256.5%) | $46.60 K(-36.1%) | $256.20 K(+9.6%) |
| Mar 2004 | - | $72.90 K(+1.5%) | $233.80 K(+31.6%) |
| Dec 2003 | - | $71.80 K(+10.6%) | $177.60 K(+46.4%) |
| Sept 2003 | - | $64.90 K(+168.2%) | $121.30 K(+69.9%) |
| June 2003 | $74.40 K(-85.6%) | $24.20 K(+44.9%) | $71.40 K(+51.3%) |
| Mar 2003 | - | $16.70 K(+7.7%) | $47.20 K(+54.8%) |
| Dec 2002 | - | $15.50 K(+3.3%) | $30.50 K(+103.3%) |
| Sept 2002 | - | $15.00 K | $15.00 K |
| June 2002 | $516.30 K(+794.8%) | - | - |
| June 2001 | $57.70 K | - | - |
FAQ
- What is EyePoint Pharmaceuticals annual revenue?
- What is the all time high annual revenue for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals annual revenue year-on-year change?
- What is EyePoint Pharmaceuticals quarterly revenue?
- What is the all time high quarterly revenue for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals quarterly revenue year-on-year change?
- What is EyePoint Pharmaceuticals TTM revenue?
- What is the all time high TTM revenue for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals TTM revenue year-on-year change?
What is EyePoint Pharmaceuticals annual revenue?
The current annual revenue of EYPT is $46.02 M
What is the all time high annual revenue for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high annual revenue is $46.02 M
What is EyePoint Pharmaceuticals annual revenue year-on-year change?
Over the past year, EYPT annual revenue has changed by +$4.61 M (+11.14%)
What is EyePoint Pharmaceuticals quarterly revenue?
The current quarterly revenue of EYPT is $10.52 M
What is the all time high quarterly revenue for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high quarterly revenue is $25.31 M
What is EyePoint Pharmaceuticals quarterly revenue year-on-year change?
Over the past year, EYPT quarterly revenue has changed by -$4.68 M (-30.77%)
What is EyePoint Pharmaceuticals TTM revenue?
The current TTM revenue of EYPT is $45.71 M
What is the all time high TTM revenue for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high TTM revenue is $50.39 M
What is EyePoint Pharmaceuticals TTM revenue year-on-year change?
Over the past year, EYPT TTM revenue has changed by +$3.19 M (+7.50%)